Bioventus Inc. BVS
NASDAQ
| 06/27/2026 | 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 153.21M | 132.09M | 157.90M | 138.65M | 147.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 153.21M | 132.09M | 157.90M | 138.65M | 147.66M |
| Cost of Revenue | 47.54M | 41.32M | 49.12M | 44.42M | 45.57M |
| Gross Profit | 105.67M | 90.77M | 108.78M | 94.23M | 102.09M |
| SG&A Expenses | 82.72M | 78.31M | 82.76M | 78.64M | 79.10M |
| Depreciation & Amortization | 1.04M | 1.11M | 1.30M | 1.40M | 1.44M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.47M | 123.20M | 136.18M | 127.39M | 129.28M |
| Operating Income | 18.73M | 8.89M | 21.72M | 11.27M | 18.38M |
| Income Before Tax | 15.31M | 4.52M | 14.14M | 4.67M | 10.31M |
| Income Tax Expenses | -20.90M | 571.00K | -3.18M | 664.00K | 1.04M |
| Earnings from Continuing Operations | 36.21M | 3.95M | 17.32M | 4.01M | 9.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.76M | -833.00K | -2.56M | -851.00K | -1.81M |
| Net Income | 33.44M | 3.11M | 14.76M | 3.16M | 7.46M |
| EBIT | 18.73M | 8.89M | 21.72M | 11.27M | 18.38M |
| EBITDA | 29.68M | 20.09M | 27.05M | 22.67M | 30.43M |
| EPS Basic | 0.49 | 0.05 | 0.22 | 0.05 | 0.11 |
| Normalized Basic EPS | 0.10 | 0.03 | 0.11 | 0.03 | 0.07 |
| EPS Diluted | 0.47 | 0.04 | 0.21 | 0.05 | 0.11 |
| Normalized Diluted EPS | 0.09 | 0.03 | 0.11 | 0.03 | 0.07 |
| Average Basic Shares Outstanding | 67.87M | 67.30M | 67.02M | 66.92M | 66.50M |
| Average Diluted Shares Outstanding | 70.84M | 70.01M | 69.26M | 68.84M | 68.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |